UY40217A - Formas de sal y solvatos de antagonistas de mci-1 - Google Patents

Formas de sal y solvatos de antagonistas de mci-1

Info

Publication number
UY40217A
UY40217A UY0001040217A UY40217A UY40217A UY 40217 A UY40217 A UY 40217A UY 0001040217 A UY0001040217 A UY 0001040217A UY 40217 A UY40217 A UY 40217A UY 40217 A UY40217 A UY 40217A
Authority
UY
Uruguay
Prior art keywords
salt
mci
solvates
antagonists
solvate forms
Prior art date
Application number
UY0001040217A
Other languages
English (en)
Spanish (es)
Inventor
D Parent Stephan
Travis Houston
Henry Morrison
S Tedrow Jason
Courtney Johnson
Melanie Bevill
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY40217A publication Critical patent/UY40217A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY0001040217A 2022-04-05 2023-04-10 Formas de sal y solvatos de antagonistas de mci-1 UY40217A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263327659P 2022-04-05 2022-04-05

Publications (1)

Publication Number Publication Date
UY40217A true UY40217A (es) 2023-10-31

Family

ID=86386785

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040217A UY40217A (es) 2022-04-05 2023-04-10 Formas de sal y solvatos de antagonistas de mci-1

Country Status (9)

Country Link
US (1) US12351588B2 (enExample)
EP (1) EP4504737A1 (enExample)
JP (1) JP2025513774A (enExample)
AU (1) AU2023249146A1 (enExample)
CA (1) CA3254998A1 (enExample)
MX (1) MX2024012192A (enExample)
TW (1) TW202404983A (enExample)
UY (1) UY40217A (enExample)
WO (1) WO2023196360A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519271A1 (en) 2022-05-04 2025-03-12 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1

Also Published As

Publication number Publication date
CA3254998A1 (en) 2023-10-12
MX2024012192A (es) 2024-11-08
US20230312602A1 (en) 2023-10-05
TW202404983A (zh) 2024-02-01
JP2025513774A (ja) 2025-04-30
US12351588B2 (en) 2025-07-08
AU2023249146A1 (en) 2024-10-10
WO2023196360A1 (en) 2023-10-12
EP4504737A1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
ECSP20078226A (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
CO2022008359A2 (es) Derivados de un inhibidor de fgfr
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
DOP2021000216A (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
MX2022001870A (es) Combinaciones y composiciones de arn con propiedades inmunoestimuladoras disminuidas.
EP4566612A3 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2020011639A (es) Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
CU24564B1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MX2022000579A (es) Combinaciones de un conjugado anticuerpo-farmaco anti-her2 y agentes quimioterapeuticos y los metodos de uso.
CL2020002157A1 (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
CR20210251A (es) Derivados de 2,3-dihidro-1h-pirrolo(3,4-c)piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer
UY40217A (es) Formas de sal y solvatos de antagonistas de mci-1
BR112021015996A2 (pt) Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes
CL2023002635A1 (es) Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1
BR112021024946A2 (pt) Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero
CO2026000531A2 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
PE20250664A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
ES2107212T3 (es) Derivados de 1,4-benzoxazina como abridores de los canales de potasio.
CL2021001547A1 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer
UY40218A (es) Formas amorfas y cristalinas de los antagonistas de mci-1
CL2024002532A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
CO2025008296A2 (es) Formas sólidas de compuestos de naftiridina
CL2023002064A1 (es) Derivados de ácido urólico sintético y métodos de uso de estos
CL2022002035A1 (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas (div. sol. n° 202002839).
PL3740492T3 (pl) Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53